Kala Bio (KALA) Net Cash Flow (2016 - 2026)
Kala Bio (KALA) posted Net Cash Flow of -$5.8 million for Q1 2026, up 57.21% sequentially from -$13.5 million in Q4 2025, and up 35.34% YoY from -$4.3 million in Q1 2025.
Kala Bio (KALA) Net Cash Flow (2016 - 2026) Analysis & Trends
Kala Bio has reported Net Cash Flow for 11 years, with the latest figure at -$5.8 million in Q1 2026.
- Quarterly Net Cash Flow rose 35.34% year-over-year to -$5.8 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$49.3 million (down 687.5% YoY) and the FY2025 annual result came in at -$43.6 million, down 15353.15% from the prior year.
- Net Cash Flow advanced to -$5.8 million in Q1 2026 per KALA's latest filing, from -$13.5 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $18.1 million in Q4 2022 and troughed at -$29.0 million in Q1 2022.
- A 5-year average of -$6.0 million and a median of -$5.8 million in 2026 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2022 and 2025: Net Cash Flow surged 155.93% in 2022, then slumped 784.13% in 2025.
- Over 5 years, Net Cash Flow stood at $18.1 million in 2022, then tumbled by 128.55% to -$5.2 million in 2023, then surged by 138.29% to $2.0 million in 2024, then tumbled by 784.13% to -$13.5 million in 2025, then surged by 57.21% to -$5.8 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered -$5.8 million, -$13.5 million, and -$10.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.52 Bn | 132.67 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 86.54 Bn | 78.55 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 65.31 Bn | 60.13 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.77 Bn | 56.64 Bn | 52.00 Mn | -183.00 Mn |
| 5 | BeOne Medicines | 42.26 Bn | 37.16 Bn | 1.53 Bn | 407.41 Mn |
| 6 | Alnylam Pharmaceuticals | 31.19 Bn | 27.88 Bn | 992.69 Mn | -496,000.00 |
| 7 | BioNTech SE | 28.71 Bn | 10.31 Bn | 668.28 Mn | -2.83 Bn |
| 8 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | -37.14 Mn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 225.59 Mn |
| 10 | Kala Bio | 9.87 Mn | 9.87 Mn | - | -5.79 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -5.79 Mn |
| Mar 31, 2026 | -5.79 Mn |
| Dec 31, 2025 | -13.54 Mn |
| Dec 31, 2025 | -13.54 Mn |
| Sep 30, 2025 | -10.85 Mn |
| Sep 30, 2025 | -10.85 Mn |
| Jun 30, 2025 | -19.09 Mn |
| Jun 30, 2025 | -19.09 Mn |
| Mar 31, 2025 | -8.96 Mn |
| Mar 31, 2025 | -8.96 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Dec 31, 2024 | 1.98 Mn |
| Sep 30, 2024 | -5.00 Mn |
| Sep 30, 2024 | -5.00 Mn |
| Jun 30, 2024 | 5.72 Mn |
| Jun 30, 2024 | 5.72 Mn |
| Mar 31, 2024 | -2.42 Mn |
| Mar 31, 2024 | -2.42 Mn |
| Dec 31, 2023 | -5.17 Mn |
| Dec 31, 2023 | -5.17 Mn |